Human immunodeficiency virus 1 envelope glycoprotein gp150 (HIV-1 Env gp150)

The HIV-1 Envelope glycoprotein gp150 is a truncated version of the gp160 precursor protein, typically consisting of the gp120 surface subunit and a modified gp41 transmembrane subunit that lacks the C-terminal cytoplasmic tail (Earl et al., 1991). This specific construct is frequently utilized in vaccine research and viral vector development because the removal of the cytoplasmic tail often results in significantly higher levels of protein expression on the cell surface compared to the full-length native gp160 (UniProt P03377). Biologically, the Env protein complex is essential for the HIV-1 life cycle, mediating the initial attachment to host CD4 receptors and co-receptors (CCR5 or CXCR4) and facilitating the fusion of the viral envelope with the host cell membrane (NIH, 2023). As the only viral protein exposed on the surface of the virion, it is the primary target for the human immune system's neutralizing antibody response and a central focus for HIV-1 vaccine design. Clinically, components of the Env complex are targeted by entry inhibitors such as Enfuvirtide, which binds to gp41 to prevent fusion, and Fostemsavir, which binds to gp120 to prevent attachment (DrugBank). However, the protein presents substantial therapeutic challenges due to its high mutational plasticity, dense glycosylation (the "glycan shield"), and the ability to mask conserved epitopes from the immune system (PubMed).

Other names

gp150Truncated HIV-1 envelope proteinHIV-1 gp150Env gp150Cytoplasmic tail-deleted HIV-1 Env

Inhibition of viral entry by binding to the gp120 or gp41 subunits, thereby preventing attachment to host CD4 receptors or blocking the conformational changes required for membrane fusion.